CRIS Current Research Information System

BARBATO, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 2.114
NA - Nord America 1.083
EU - Europa 802
SA - Sud America 140
AF - Africa 91
OC - Oceania 6
Totale 4.236
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.058
VN - Vietnam 946
SG - Singapore 411
CN - Cina 408
IT - Italia 318
HK - Hong Kong 115
BR - Brasile 98
DE - Germania 87
GB - Regno Unito 77
KR - Corea 64
FR - Francia 63
IN - India 51
SE - Svezia 51
NL - Olanda 45
FI - Finlandia 41
CI - Costa d'Avorio 30
IE - Irlanda 28
JP - Giappone 28
RU - Federazione Russa 26
ZA - Sudafrica 19
SC - Seychelles 18
AR - Argentina 17
CA - Canada 14
TG - Togo 12
PL - Polonia 11
BD - Bangladesh 10
AT - Austria 9
IQ - Iraq 9
TW - Taiwan 9
PH - Filippine 8
TH - Thailandia 8
ES - Italia 7
JO - Giordania 7
BG - Bulgaria 6
EC - Ecuador 6
ID - Indonesia 6
MX - Messico 6
AU - Australia 5
CZ - Repubblica Ceca 5
EE - Estonia 5
SA - Arabia Saudita 5
TR - Turchia 5
UZ - Uzbekistan 5
CL - Cile 4
CO - Colombia 4
HR - Croazia 4
MY - Malesia 4
UA - Ucraina 4
AE - Emirati Arabi Uniti 3
CH - Svizzera 3
IL - Israele 3
PK - Pakistan 3
PY - Paraguay 3
UY - Uruguay 3
VE - Venezuela 3
CR - Costa Rica 2
EG - Egitto 2
GH - Ghana 2
GR - Grecia 2
KE - Kenya 2
LT - Lituania 2
MA - Marocco 2
NP - Nepal 2
RO - Romania 2
RS - Serbia 2
TN - Tunisia 2
AL - Albania 1
BO - Bolivia 1
BS - Bahamas 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
KN - Saint Kitts e Nevis 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
MT - Malta 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
PE - Perù 1
QA - Qatar 1
SK - Slovacchia (Repubblica Slovacca) 1
ZM - Zambia 1
Totale 4.236
Salva come PNG Salva come JPEG
Città #
Singapore 290
Ho Chi Minh City 284
Hanoi 232
Ashburn 143
Bologna 142
Hefei 120
Hong Kong 109
Chandler 102
Dallas 85
San Jose 77
Fairfield 64
Seoul 55
Southend 45
Santa Clara 44
Haiphong 41
Lauterbourg 36
Abidjan 30
Beijing 30
Dublin 24
Los Angeles 22
Princeton 22
Tokyo 21
Council Bluffs 20
Wilmington 20
Redmond 19
Boardman 18
Houston 18
Lappeenranta 18
New York 18
Seattle 18
Woodbridge 18
Cambridge 17
Helsinki 17
Da Nang 16
São Paulo 16
Biên Hòa 15
Dongguan 15
Milan 15
Quận Bình Thạnh 14
Johannesburg 13
Shenzhen 13
Ann Arbor 12
Ha Long 12
Lomé 12
Ninh Bình 12
Thái Nguyên 12
Bengaluru 11
Frankfurt am Main 10
Guangzhou 10
Munich 10
Redondo Beach 10
Điện Bàn 10
Can Tho 9
Hyderabad 9
Quận Một 9
Rome 9
Amsterdam 8
Atlanta 8
Buffalo 8
Nanjing 8
Shanghai 8
Vũng Tàu 8
Amman 7
Bắc Giang 7
Bắc Ninh 7
Chicago 7
Hải Dương 7
Bến Tre 6
Fabriano 6
Madrid 6
Quận Phú Nhuận 6
Sofia 6
Turku 6
Vinh 6
Warsaw 6
Bremen 5
Falkenstein 5
Jakarta 5
Mexico City 5
Nuremberg 5
Paris 5
Quảng Ngãi 5
Rio de Janeiro 5
Stockholm 5
Wuhan 5
Ankara 4
Berlin 4
Bettystown 4
Brooklyn 4
Cernusco sul Naviglio 4
Changsha 4
Chongqing 4
Curitiba 4
Florence 4
Huế 4
Lang Son 4
Nam Định 4
Orem 4
Padova 4
Quận Năm 4
Totale 2.734
Salva come PNG Salva come JPEG
Nome #
Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma 706
Hypoxia Decreases ROS level in human fibroblasts 213
Standardization of 18F-FDG-PET/CT According to Deauville Criteria for Metabolic Complete Response Definition in Newly Diagnosed Multiple Myeloma 206
Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study 204
Clinical Presentation and Long‐Term Survival Outcomes of Patients With Monoclonal Gammopathy of Renal Significance (MGRS): A Multicenter Retrospective Study 200
Role of serum-free light chain assay for defining response and progression in immunoglobulin secretory multiple myeloma 185
Diagnostic Innovations: Advances in imaging techniques for diagnosis and follow-up of multiple myeloma 182
Idecabtagene vicleucel (ide-cel) for the treatment of triple-class exposed relapsed and refractory multiple myeloma 179
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma 168
The inhibitor protein (IF1) of the F1F0-ATPase modulates human osteosarcoma cell bioenergetics 161
Emerging and current treatment combinations for transplant-ineligible multiple myeloma patients 127
null 125
Role of Imaging in the Evaluation of Minimal Residual Disease in Multiple Myeloma Patients 118
Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma 114
Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review 113
Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma 107
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial 105
Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cell collection in Multiple Myeloma 104
The role of the ATPase inhibitor factor 1 (IF(1)) in cancer cells adaptation to hypoxia and anoxia 100
null 96
How I Treat High-risk Multiple Myeloma 96
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational study 96
MicroRNAs in Oncogenesis and Tumor Suppression 84
T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS 83
Bispecific Antibodies and CAR T in Multiple Myeloma: Appropriate Selection of Patients and Sequencing 76
Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home 74
Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 71
Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies? 70
Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and lymphoplasmacytic lymphoma 69
A multicenter observational retrospective study of second-line treatment with daratumumab–bortezomib–dexamethasone (DaraVd) in multiple myeloma patients refractory to lenalidomide 51
Correction: Forcing Ahead: Second-Line Treatment Options for Lenalidomide-Refractory Multiple Myeloma 49
Totale 4.332
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.676
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.676
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202165 0 0 0 0 0 0 0 0 0 11 9 45
2021/2022255 6 10 10 14 17 7 3 18 19 33 75 43
2022/2023330 42 46 6 52 14 31 11 16 67 10 25 10
2023/2024131 10 17 6 7 8 20 9 38 2 4 5 5
2024/2025620 26 27 52 60 57 18 41 15 25 68 75 156
2025/20262.638 299 646 195 211 195 161 223 100 459 149 0 0
Totale 4.332